Form 4: Phreesia Director Lisa Egbuonu-Davis Reports RSU Grant and Stock Sale Under 10b5-1 Plan
Insider Transaction Report
Phreesia, Inc. Director Lisa Egbuonu-Davis reported the acquisition of 6,700 Restricted Stock Units and the sale of 2,802 shares of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- Lisa Egbuonu-Davis, a Director of Phreesia, Inc. (PHR), reported two transactions involving the company's common stock.
- On June 25, 2025, Ms. Egbuonu-Davis acquired 6,700 Restricted Stock Units (RSUs) at a price of $27.61 per share. These RSUs are part of the Phreesia, Inc. 2019 Stock Option and Incentive Plan and will vest in full upon the earlier of June 25, 2026, or the next annual meeting of stockholders.
- On June 26, 2025, she disposed of 2,802 shares of common stock at a price of $27.67 per share. This sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Ms. Egbuonu-Davis on September 24, 2024.
- Following these transactions, Ms. Egbuonu-Davis beneficially owns 22,037 shares of Phreesia, Inc. common stock directly.
Sentiment
Score: 5
Explanation: The document reports routine insider transactions, including an RSU grant and a sale under a 10b5-1 plan. These are generally neutral events, reflecting standard compensation practices and pre-planned liquidity management, rather than a strong positive or negative signal about the company's immediate prospects.
Positives
- The acquisition of 6,700 Restricted Stock Units (RSUs) aligns the director's interests with long-term shareholder value, as these units vest over time.
- The sale of shares was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent transaction rather than an immediate reaction to new information.
Negatives
- The sale of 2,802 shares by a director, even under a 10b5-1 plan, represents a reduction in direct ownership, which some investors might interpret as a slight negative.
Future Outlook
The document does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the vesting schedule for the granted Restricted Stock Units.
Industry Context
This Form 4 filing details routine insider transactions, specifically a director's acquisition of equity compensation and a sale under a pre-arranged trading plan. Such transactions are common across publicly traded companies, particularly in the healthcare technology sector where equity-based compensation is a standard practice for attracting and retaining executive talent. The use of a Rule 10b5-1 plan reflects a commitment to transparent and pre-scheduled insider trading, which is a common practice to avoid accusations of trading on material non-public information.
Comparison to Industry Standards
- The use of Restricted Stock Units (RSUs) as a form of equity compensation and the execution of stock sales via Rule 10b5-1 trading plans are standard practices for directors and executives in publicly traded companies, including those in the healthcare technology sector like Phreesia, Inc.
- Companies such as Veeva Systems (VEEV), Cerner Corporation (CERN, now Oracle Health), and Teladoc Health (TDOC) also frequently utilize similar compensation structures and trading mechanisms for their insiders.
- The specific values and volumes of shares traded are typical for individual director compensation and portfolio management, and do not indicate any significant deviation from industry norms.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Delegation | Allison Hoffman, as attorney-in-fact for multiple Phreesia officers and directors, including Lisa Egbuonu-Davis, has appointed Autumn Simpson as a substitute attorney-in-fact with full power of substitution for SEC filings. This delegation does not revoke Allison Hoffman's own powers. | 2025-06-23 | This is a procedural update to the company's legal and compliance framework, ensuring continuity in the filing of SEC documents on behalf of insiders. It enhances operational efficiency for regulatory compliance without directly impacting corporate governance policies or shareholder rights. |
Related Party Transactions
- The reported transactions involve a director of Phreesia, Inc., Lisa Egbuonu-Davis, acquiring Restricted Stock Units as part of her compensation and selling shares, which are considered related party transactions due to her insider status. These transactions are disclosed as required by SEC regulations.
Stakeholder Impact
- Shareholders: The RSU grant aligns the director's interests with long-term shareholder value. The sale under a 10b5-1 plan provides transparency regarding insider stock transactions.
- Employees: The RSU grant is a form of equity compensation, which is a common practice that can impact employee morale and retention if similar plans are available to other employees.
Next Steps
- The 6,700 Restricted Stock Units are scheduled to vest in full upon the earlier of June 25, 2026, or the next annual meeting of Phreesia, Inc. stockholders.
Key Dates
| Date | Description |
|---|---|
| 2021-01-12 | Date of Power of Attorney for Chaim Indig, David Linetsky, Ramin Sayar, Mark Smith, Michael Weintraub, and Allison Hoffman. |
| 2021-01-19 | Date of Power of Attorney for Ed Cahill. |
| 2021-01-31 | Date of Power of Attorney for Lainie Goldstein, Gillian Munson, Evan Roberts, and Amy VanDuyn. |
| 2023-03-24 | Date of Power of Attorney for Balaji Gandhi. |
| 2023-06-05 | Date of Power of Attorney for Lisa Egbuonu-Davis. |
| 2024-06-25 | Date of Power of Attorney for Yvonne Hui. |
| 2024-09-24 | Date the Rule 10b5-1 trading plan was adopted by Lisa Egbuonu-Davis. |
| 2025-06-23 | Effective date of the Substitute Power of Attorney appointing Autumn Simpson. |
| 2025-06-25 | Date of acquisition of 6,700 Restricted Stock Units by Lisa Egbuonu-Davis. |
| 2025-06-26 | Date of disposition of 2,802 shares of common stock by Lisa Egbuonu-Davis. |
| 2025-06-27 | Date the Form 4 was signed. |
| 2026-06-25 | Earliest vesting date for the 6,700 Restricted Stock Units. |
Keywords
Phreesia Inc, PHR, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Rule 10b5-1 Plan, Stock Sale, Director Compensation, Equity Compensation, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.